Background: Dysplastic neutrophils commonly show at least 2/3 reduction of the content of cytoplasmic granules by morphologic examination. Recognition of less granulated dysplastic neutrophils by human eyes is difficult and prone to inter-observer variability. To tackle this problem, we proposed a new deep learning model (DysplasiaNet) able to automatically recognize the presence of hypogranulated dysplastic neutrophils in peripheral blood.
Methods: Eight models were generated by varying convolutional blocks, number of layer nodes and fully connected layers. Each model was trained for 20 epochs. The five most accurate models were selected for a second stage, being trained again from scratch for 100 epochs. After training, cut-off values were calculated for a granularity score that discerns between normal and dysplastic neutrophils. Furthermore, a threshold value was obtained to quantify the minimum proportion of dysplastic neutrophils in the smear to consider that the patient might have a myelodysplastic syndrome (MDS). The final selected model was the one with the highest accuracy (95.5%).
Results: We performed a final proof of concept with new patients not involved in previous steps. We reported 95.5% sensitivity, 94.3% specificity, 94% precision, and a global accuracy of 94.85%.
Conclusions: The primary contribution of this work is a predictive model for the automatic recognition in an objective way of hypogranulated neutrophils in peripheral blood smears. We envision the utility of the model implemented as an evaluation tool for MDS diagnosis integrated in the clinical laboratory workflow.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2021.104479 | DOI Listing |
CPT Pharmacometrics Syst Pharmacol
December 2024
Clinical Pharmacology, AbbVie Inc., Ludwigshafen am Rhein, Germany.
Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease-induced and treatment-related cytopenias. Venetoclax, a selective BCL-2 inhibitor, in combination with azacitidine, a hypomethylating agent, is currently being investigated in patients with previously untreated higher-risk MDS.
View Article and Find Full Text PDFAm J Surg Pathol
September 2024
Department of Pathology, University of California, San Francisco, CA.
Although the increased risk of colorectal neoplasia in patients with both primary sclerosing cholangitis (PSC) and ulcerative colitis (UC; termed PSC-UC) is well documented, the mechanism through which concomitant PSC increases the risk of colorectal neoplasia remains unclear. Given that the risk of colorectal neoplasia in UC is positively correlated with increased histologic inflammation, this study sought to investigate whether increased histologic inflammation could be used to stratify the risk of dysplasia development in patients with PSC-UC. Twenty patients with PSC-UC and dysplasia were compared with 30 control patients with PSC-UC who had no history of neoplasia.
View Article and Find Full Text PDFAm J Hematol
July 2024
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Chronic neutrophilic leukemia (CNL) is a rare BCR::ABL1-negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic "[MDS]/MPN with neutrophilia" per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death.
View Article and Find Full Text PDFAm J Surg Pathol
June 2024
Department of Pathology, University of California at San Francisco, San Francisco, CA.
Serrated epithelial change (SEC) in inflammatory bowel disease is most often defined as hyperplastic polyp-like mucosal change detected on random biopsies. Although SEC has been reported to be associated with an increased risk of synchronous and/or metachronous colorectal neoplasia, it remains unknown if SEC represents a form of dysplastic lesion despite the lack of morphologic evidence of dysplasia. Since the risk of colorectal neoplasia in ulcerative colitis (UC) is positively correlated with increased histologic inflammation, this study investigated if increased colonic inflammation is an independent risk factor for SEC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!